Ultime notizie per abrdn Life Sciences (NYSE:HQL) Azioni

Tekla Life Sciences Invts

abrdn Life Sciences

Tekla Life Sciences

abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.

abrdn Life Sciences Investors Shares of Beneficial Interest

abrdn Life Sciences Investors

Although U.S. stocks closed higher on Monday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company&#8217;s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Lake Shore Bancorp</h3>
<ul>
<li>The Trade: Lake Shore Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSBK#NASDAQ">LSBK</a>) Director Kevin M. Sanvidge <a href="https://www.benzinga.com/quote/LSBK/analyst-ratings">acquired a total of 3,000 shares</a> an average price of $10.81. To acquire these shares, it cost around $32,442..</li>
<li>What's Happening: On April 22, Lake Shore Bancorp posted a decline in quarterly EPS.</li>
<li>What Lake Shore Bancorp Does: Lake Shore Bancorp Inc operates as a savings and loan holdings company.</li>
</ul>
<h3 class="wp-block-heading">Auburn National Bancorporation</h3>
<ul>
<li>The Trade: Auburn National Bancorporation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUBN#NASDAQ">AUBN</a>) President/CEO David A Hedges acquired a total of 10,000 shares at an average price of $17.60. To acquire these shares, it cost around $176,000.</li>
<li>What's Happening: On April 24, Auburn National Bancorporation posted a decline in quarterly sales.</li>
<li>What Auburn National Bancorporation Does: Auburn National Bancorp Inc operates as a bank holding company, which offers checking, savings, transaction deposit accounts and certificates of deposit, and is an active residential mortgage lender in its primary service area.</li>
</ul>
Don&#8217;t forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<h3 class="wp-block-heading">Abrdn Life Sciences Investors</h3>
<ul>
<li>The Trade: Abrdn Life Sciences Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HQL#NYSE">HQL</a>) 10% owner Boaz Weinstein <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 120,304 shares</a> at an average price of $13.00. To acquire these shares, it cost around $1.56 million.</li>
<li>What's Happening: The company's stock gained around 13% over the past six months.</li>
<li>What Abrdn Life Sciences Investors Does: abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company.</li>
</ul>
Now Read this: <a href="https://www.benzinga.com/news/earnings/24/04/38509641/mcdonalds-likely-to-report-higher-q1-earnings-here-are-the-recent-forecast-changes-from-wall-street">McDonald&#8217;s Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>

Long Ideas

News

Insider Trades

Pre-Market Outlook

Markets

AUBN

LSBK

Around $1.5M Bet On Abrdn Life Sciences Investors? Check Out These 3 Stocks Insiders Are Buying

Saba Capital Management, Reported A 5.31% Stake In abrdn Life Sciences; Saba Acquired The Shares Because They Believe That The Common Shares Are Undervalued And Represent An Attractive Investment Opportunity

Wednesday marks the last chance for investors to receive the next dividend payout from Tekla Life Sciences Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HQL#NYSE">HQL</a>). 
<h3>What's Happening</h3>
The company announced on Tuesday that it would pay shareholders a quarterly dividend of 32 cents per share. On Thursday, Tekla Life Sciences Invts will go ex-dividend, meaning the stock will trade lower to reflect that payout. In other words, the stock will likely open 32 cents lower than it would have opened on any other day.
In order to be eligible to receive a company's dividend, shareholders must own the stock prior to the ex-dividend date—in this case, Thursday. Shareholders who own HQL as of the end of Wednesday's session are eligible to receive the 32 cents dividend payout for every share that they own. 
According to the company, this dividend will be paid out to shareholders on September 29, 2023. Investors will then be able to either reinvest those dividends back into the stock or use the payment in some other way. 
<a href="https://www.benzinga.com/stock//dividends">Click here</a> to find details on Tekla Life Sciences Invts's previous dividends.
To keep track of which companies are distributing dividends, <a href="https://www.benzinga.com/calendars/dividends">click here</a> to visit our Dividends Calendar.

Dividends

Wednesday Is Your Last Chance To Buy Tekla Life Sciences Invts Before The Dividend Payout

Tuesday marks the last chance for investors to receive the next dividend payout from Tekla Life Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HQL#NYSE">HQL</a>).
<h3>What&#39;s Happening</h3>
The company announced on Tuesday that it would pay shareholders a quarterly dividend of 31 cents per share. On Wednesday, Tekla Life Sciences will go ex-dividend, meaning the stock will trade lower to reflect that payout. In other words, the stock will likely open 31 cents lower than it would have opened on any other day.
In order to be eligible to receive a company&#39;s dividend, shareholders must own the stock prior to the ex-dividend date&mdash;in this case, Wednesday. Shareholders who own HQL as of the end of Tuesday&#39;s session are eligible to receive the 31 cents dividend payout for every share that they own.
According to the company, this dividend will be paid out to shareholders on December 30, 2022. Investors will then be able to either reinvest those dividends back into the stock or use the payment in some other way.
<a href="https://www.benzinga.com/stock//dividends">Click here</a> to find details on Tekla Life Sciences&#39;s previous dividends.
To keep track of which companies are distributing dividends, <a href="https://www.benzinga.com/calendars/dividends">click here</a> to visit our Dividends Calendar.

Tekla Life Sciences: Dividend Insights

Wednesday marks the last chance for investors to receive the next dividend payout from Tekla Life Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HQL#NYSE">HQL</a>).
<h3>What&#39;s Happening</h3>
The company announced on Tuesday that it would pay shareholders a quarterly dividend of 31&nbsp;per share. On Thursday, Tekla Life Sciences will go ex-dividend, meaning the stock will trade lower to reflect that payout. In other words, the stock will likely open 31 lower than it would have opened on any other day.
In order to be eligible to receive a company&#39;s dividend, shareholders must own the stock prior to the ex-dividend date&mdash;in this case, Thursday. Shareholders who own HQL as of the end of Wednesday&#39;s session are eligible to receive the 31 dividend payout for every share that they own.
According to the company, this dividend will be paid out to shareholders on September 30, 2022. Investors will then be able to either reinvest those dividends back into the stock or use the payment in some other way.
To stay up-to-date with the companies that are announcing their dividends, <a href="https://www.benzinga.com/calendars/dividends">click here</a> to visit our Dividends Calendar.

Wednesday marks the last chance for investors to receive the next dividend payout from Tekla Life Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HQL#NYSE">HQL</a>). 
<h3>What's Happening</h3>
The company announced on Tuesday that it would pay shareholders a quarterly dividend of $0.35 per share. On Thursday, Tekla Life Sciences will go ex-dividend, meaning the stock will trade lower to reflect that payout. In other words, the stock will likely open $0.35 lower than it would have opened on any other day.
In order to be eligible to receive a company's dividend, shareholders must own the stock prior to the ex-dividend date—in this case, Thursday. Shareholders who own HQL as of the end of Wednesday's session are eligible to receive the $0.35 dividend payout for every share that they own. 
According to the company, this dividend will be paid out to shareholders on June 30, 2022. Investors will then be able to either reinvest those dividends back into the stock or use the payment in some other way. 
<a href="https://www.benzinga.com/stock//dividends">Click here</a> to find details on Tekla Life Sciences's previous dividends.
To keep track of which companies are distributing dividends, <a href="https://www.benzinga.com/calendars/dividends">click here</a> to visit our Dividends Calendar.

Tekla Life Sciences's Ex-Dividend Date Is Thursday, Here's What You Need To Know

<h1>Tekla Life Sciences Investors Declares Distribution</h1>
On February 16, 2021, Tekla Life Sciences Investors declared a distribution of&nbsp;$0.43&nbsp;per share. The record date for the distribution is February 26, 2021 and the payable date is March 31, 2021. The Fund will trade ex-distribution on February 25, 2021.
This distribution will automatically be paid in newly issued shares of the Fund unless otherwise instructed by the shareholder. The shares will be valued at the lower of the net asset value or market price on the pricing date, March 23, 2021. Fractional shares will generally be settled in cash, except for registered shareholders with book entry accounts at the transfer agent who will have whole and fractional shares added to their account.
Shareholders may request to be paid in cash instead of shares by responding to the bank, brokerage or nominee who holds the shares if the shares are in &quot;street name&quot; or by filling out an election card received from Computershare Investor Services shortly after the record date if the shares are in registered form. The bank, brokerage or nominee who holds the shares must advise the Depository Trust Company (&quot;DTC&quot;) as to their full and fractional share requirements by March 22, 2021. Written notification for the election of cash instead of stock by registered shareholders must be received by Computershare Investor Services prior to March 22, 2021.
Tekla Life Sciences Investors (NYSE:<a class="ticker" href="/stock/HQL#NYSE">HQL</a>) is a closed-end fund that invests in public and private companies in the life sciences industry. Tekla Capital Management LLC, based in Boston, serves as Investment Adviser to the Fund. Shares of the Fund can be purchased on the New York Stock Exchange through any securities broker.
For additional information, please consult&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.teklacap.com&amp;esheet=52379768&amp;newsitemid=20210216005881&amp;lan=en-US&amp;anchor=www.teklacap.com&amp;index=1&amp;md5=46e014a2a639bdf585e9d0175e3789ef">www.teklacap.com</a>&nbsp;or call (877)-855-3434.
<img alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20210216005881r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" />
View source version on businesswire.com:&nbsp;<a href="https://www.businesswire.com/news/home/20210216005881/en/">https://www.businesswire.com/news/home/20210216005881/en/</a>

Tekla Life Sciences Increases Dividend From $0.40 To $0.43

Penny Stocks

Small Cap

Intraday Update

Movers

Trading Ideas

AACQ

ACAM

ACND

ACRS

ACTC

ADOC

ADTN

AEHL

AIRG

ALAC

ALLK

ALLY

AMBA

AMCI

ANDA

APXT

AQMS

ARVN

ASML

ASPN

ATEC

ATOM

ATRC

ATUS

ATVI

AVAN

AVGO

AVNT

BBIO

BCOV

BECN

BEEM

BIPC

BLDP

BLDR

BLNK

BMCH

BNED

BOWX

BSET

BTAQ

BTAQU

BURL

BWEN

CAMT

CELH

CGNX

CHUY

CLLS

CLSK

CNHI

CPRI

CRHC

CRIS

CRSP

CSCW

CVET

CVLT

DBDR

DCBO

DFHT

DGNS

DMAC

DMYD

DMYT

EARN

EGOV

ENPH

EPIX

EQOS

ERES

ERII

ETAC

Stocks That Hit 52-Week Highs On Monday

ALTR

AMED

APLS

ARWR

ASAQ

CDAK

CDAY

CFII

CLII

CLPT

CMLF

CORT

CPST

CRVL

CRWD

CSSE

DAVA

DZSI

EGHT

EIDX

EXPO

FAII

FIII

FLNT

GDYN

GEVO

GHIV

GNRC

GTIM

GWAC

HCAT

HCFT

IART

IPGP

IRDM

KYMR

LESL

LGVW

LUNA

MANH

MSGE

MTSI

NGMS

Stocks That Hit 52-Week Highs On Thursday

AAXN

ABST

ADPT

ADSK

AEYE

AGYS

AKTS

ALGN

ALPN

ALRM

AMRC

AMSC

ANSS

APPF

APTV

ARGX

ATEN

ATHA

BALY

BASI

BGFV

BLFS

BOMN

BPMC

BRLI

BSTZ

CALX

CDMO

CDNA

CDNS

CDXS

CERS

CGRO

CHKP

CHNG

CLDR

CLNE

CNMD

CNNE

COHU

COOP

CREE

CRNC

CRTO

CSIQ

CTRN

CVNA

CWEN

CYBR

DJCO

Stocks That Hit 52-Week Highs On Wednesday

Comments

abrdn Life Sciences

Notizie

Ultime notizie per abrdn Life Sciences (NYSE:HQL) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO